News from

Immunology

Reset All Filters
176 Results
Kathleen Hall Jamieson, Carl June elected to National Academy of Sciences
Two people side by side in different images. In the one on the left, the person stands in an office and a blue suit, hands crossed low in front. In the one on the right is a person in a tie and white coat that reads, "Carl H. June, M.D. Abramson Cancer Center"

Kathleen Hall Jamieson and Carl June are among more than 140 new members elected to the National Academy of Sciences. (Image: Eric Sucar (L) and Courtesy of Penn Medicine)

Kathleen Hall Jamieson, Carl June elected to National Academy of Sciences

The researchers, from the Annenberg Public Policy Center and the Perelman School of Medicine, join a class of honored scholars recognized for their unique and ongoing contributions to original research.

Michele W. Berger, Michael Rozansky , John Infanti

Tailoring treatment for triple-negative breast cancer
Fluorescent microscopic image shows mammary gland cells

Researchers from Penn Vet found that that the protein Elf5 in mammary tumors plays a role in the disease’s progression and spread. Cells with Elf5 are noted in green above. (Image: Snahlata Singh and Rumela Chakrabarti)

 

 

Tailoring treatment for triple-negative breast cancer

Research led by the School of Veterinary Medicine’s Rumela Chakrabarti identified a molecular pathway responsible for the disease’s progression and spread.

Katherine Unger Baillie

Racing to deliver a vaccine to the masses
vaccine with syringe

Racing to deliver a vaccine to the masses

While the world works to flatten the curve, scientists at Penn and Wistar hope to deliver the COVID-19 pandemic’s silver bullet: a vaccine that effectively protects people from infection.

Katherine Unger Baillie

Defect driving resistance to CAR T therapy identified
A CAR T cell interacting with a cancer cell

A CAR T cell interacting with a cancer cell.

Defect driving resistance to CAR T therapy identified

A new study identifies the mechanism that prevents cell death, and can guide future immunotherapy strategies in patients whose blood cancers are resistant to CAR T therapy.

Penn Today Staff

Penn nanoparticles are less toxic to T cells engineered for cancer immunotherapy
An artist’s illustration of nanoparticles transporting mRNA into a T cell, allowing the latter to express surface receptors that recognize cancer cells.

An artist’s illustration of nanoparticles transporting mRNA into a T cell (blue), allowing the latter to express surface receptors that recognize cancer cells (red). (Image: Ryan Allen, Second Bay Studios)

Penn nanoparticles are less toxic to T cells engineered for cancer immunotherapy

By using messenger RNA across the T cell’s membrane via a nanoparticle instead of a DNA-rewriting virus on extracted T cells, CAR T treatments could have fewer side effects.

Penn Today Staff

These overlooked global diseases take a turn under the microscope
ebola virus through a microscope

In an experiment by the School of Veterinary Medicine’s Ronald Harty and Bruce Freedman, virus-like particles of Ebola (in green and yellow), which mimic the process by which the authentic Ebola virus spreads, exit a cell along filaments of actin (in red), a structural protein. Harty and Freedman are designing compounds to block this process, increasing the likelihood an infected individual could recover. (Image: Gordon Ruthel/School of Veterinary Medicine)

These overlooked global diseases take a turn under the microscope

Faculty at the School of Veterinary Medicine target neglected tropical diseases with advanced science, cross-disciplinary collaborations, and work in the lab and the field.

Katherine Unger Baillie

Positive results in first-in-U.S. trial of CRISPR-edited immune cells
microscopic rendering of CRISPR/Cas9

3D render of the CRISPR/Cas9 genome editing system.

Positive results in first-in-U.S. trial of CRISPR-edited immune cells

Genetically editing a cancer patient’s immune cells using CRISPR/Cas9 technology, then infusing those cells back into the patient appears safe and feasible based on early data from the first-ever clinical trial to test the approach in humans in the United States.

Penn Today Staff